vs
Side-by-side financial comparison of Nakamoto Inc. (NAKA) and Prime Medicine, Inc. (PRME). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $444.9K, roughly 1.9× Nakamoto Inc.). Nakamoto Inc. runs the higher net margin — 8374.2% vs -5498.7%, a 13872.9% gap on every dollar of revenue. On growth, Nakamoto Inc. posted the faster year-over-year revenue change (-26.3% vs -61.6%).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
NAKA vs PRME — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $444.9K | $838.0K |
| Net Profit | $37.3M | $-46.1M |
| Gross Margin | — | — |
| Operating Margin | -41198.2% | -5800.5% |
| Net Margin | 8374.2% | -5498.7% |
| Revenue YoY | -26.3% | -61.6% |
| Net Profit YoY | 3820.2% | -9.0% |
| EPS (diluted) | $0.68 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $444.9K | $838.0K | ||
| Q3 25 | $388.2K | $1.2M | ||
| Q2 25 | $408.5K | $1.1M | ||
| Q1 25 | $579.7K | $1.5M | ||
| Q4 24 | $603.9K | $2.2M | ||
| Q3 24 | $647.9K | — | ||
| Q2 24 | $639.1K | $0 | ||
| Q1 24 | $829.0K | $591.0K |
| Q4 25 | $37.3M | $-46.1M | ||
| Q3 25 | $-86.0M | $-50.6M | ||
| Q2 25 | $-2.4M | $-52.6M | ||
| Q1 25 | $-1.0M | $-51.9M | ||
| Q4 24 | $-1.0M | $-42.3M | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | $-1.3M | $-55.3M | ||
| Q1 24 | $-282.3K | $-45.8M |
| Q4 25 | -41198.2% | -5800.5% | ||
| Q3 25 | -2680.4% | -4406.0% | ||
| Q2 25 | -585.4% | -4787.2% | ||
| Q1 25 | -179.7% | -3603.3% | ||
| Q4 24 | -169.3% | -2025.7% | ||
| Q3 24 | -162.0% | — | ||
| Q2 24 | -162.3% | — | ||
| Q1 24 | -28.6% | -8179.5% |
| Q4 25 | 8374.2% | -5498.7% | ||
| Q3 25 | -22162.2% | -4129.1% | ||
| Q2 25 | -590.9% | -4716.7% | ||
| Q1 25 | -179.1% | -3568.8% | ||
| Q4 24 | -165.8% | -1936.6% | ||
| Q3 24 | -156.5% | — | ||
| Q2 24 | -206.5% | — | ||
| Q1 24 | -34.1% | -7743.0% |
| Q4 25 | $0.68 | $-0.22 | ||
| Q3 25 | $-0.42 | $-0.32 | ||
| Q2 25 | $-0.35 | $-0.41 | ||
| Q1 25 | $-0.17 | $-0.40 | ||
| Q4 24 | $-0.18 | $-0.31 | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.26 | $-0.46 | ||
| Q1 24 | $-0.06 | $-0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.6M | $63.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $514.3M | $120.9M |
| Total Assets | $730.6M | $342.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.6M | $63.0M | ||
| Q3 25 | $24.2M | $71.4M | ||
| Q2 25 | $6.0M | $53.8M | ||
| Q1 25 | $1.1M | $91.9M | ||
| Q4 24 | $2.3M | $182.5M | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $4.7M | $55.6M | ||
| Q1 24 | $287.4K | $94.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $64.4K | — | ||
| Q4 24 | $148.8K | — | ||
| Q3 24 | $205.6K | — | ||
| Q2 24 | $254.7K | — | ||
| Q1 24 | $710.0K | — |
| Q4 25 | $514.3M | $120.9M | ||
| Q3 25 | $477.6M | $161.8M | ||
| Q2 25 | $9.0M | $60.9M | ||
| Q1 25 | $1.5M | $106.9M | ||
| Q4 24 | $2.6M | $153.1M | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $4.4M | $196.6M | ||
| Q1 24 | $-383.1K | $243.8M |
| Q4 25 | $730.6M | $342.7M | ||
| Q3 25 | $692.4M | $385.0M | ||
| Q2 25 | $9.9M | $279.0M | ||
| Q1 25 | $2.6M | $328.2M | ||
| Q4 24 | $3.7M | $297.5M | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $5.5M | $259.7M | ||
| Q1 24 | $799.3K | $311.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-23.5M | $-37.3M |
| Free Cash FlowOCF − Capex | — | $-37.5M |
| FCF MarginFCF / Revenue | — | -4480.4% |
| Capex IntensityCapex / Revenue | — | 34.6% |
| Cash ConversionOCF / Net Profit | -0.63× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-167.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-23.5M | $-37.3M | ||
| Q3 25 | $-13.2M | $-35.0M | ||
| Q2 25 | $-1.9M | $-41.4M | ||
| Q1 25 | $-865.1K | $-48.9M | ||
| Q4 24 | $-3.1M | $16.2M | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | $-913.5K | $-45.5M | ||
| Q1 24 | $-213.4K | $-67.7M |
| Q4 25 | — | $-37.5M | ||
| Q3 25 | — | $-35.3M | ||
| Q2 25 | — | $-43.0M | ||
| Q1 25 | — | $-51.3M | ||
| Q4 24 | $-3.1M | $14.5M | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | — | $-47.4M | ||
| Q1 24 | $-224.6K | $-70.0M |
| Q4 25 | — | -4480.4% | ||
| Q3 25 | — | -2880.5% | ||
| Q2 25 | — | -3855.1% | ||
| Q1 25 | — | -3526.8% | ||
| Q4 24 | -511.2% | 662.1% | ||
| Q3 24 | -161.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -27.1% | -11849.6% |
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 141.0% | ||
| Q1 25 | — | 166.6% | ||
| Q4 24 | 2.2% | 82.0% | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 1.3% | 393.2% |
| Q4 25 | -0.63× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
